Ua loaa epekema maikaʻi hopena o ka hoao ana o ka hou lāʻau no ka leukemia

ʻepekema, ua kauoha aku e hana i kekahi laau no ka leukemia, i hookahi manawa hou i ho'āʻo ai i ka hoʻokōʻia. I ka lapaʻau e hookolokolo ai hoikeia mai e kaʻeho ma ka 71% o nā mea maʻi me ka maʻi leukemia ua hoʻemi 'ole i ka nalowale loa.

High-kamepiula pae

Ke ao, kona hualoaʻa i paʻiʻia ma ka Pai o ka lapaʻau Oncology, mālama 'ia me ke komo' ana o ka 24 hoʻomanawanui iki mai me ka maʻi lymphocytic leukemia no ka mea a nā kūlana kanaka i Ua ineffective. I ka makahiki o ka hoʻomanawanui iki mai kaulua mai 40 a hiki i 73 makahiki. Eia hou, e komo i loko o ke ao kela mea keia mea i loaa mai ka awelika o ka elimaʻano o ka Inc, me ka iapaau ana o "Ibrutinib" - he kaiāulu hoʻohana lāʻau 'ana i kēia' ano o ka maʻi 'aʻai. Ua waiho aku i komo ma kiʻekiʻe kamepiula me ka haʻahaʻa ola kōmi.

lapaʻau e hookolokolo ai

A kime mai ka Research Center Freda Hatchinsona Cancer hoʻohana i kakahiaka nui lapaʻau i kapa immunotherapy timoralnogo mea loaʻa (CAR). Me kēiaʻano o ka Inc, ke hoʻomanawanui i ka iho T keena loko mai o ke koko, a me ka loli ma ka keʻena hoʻokolohua ana. Ma keia hihia, ka mea, ua ua Hoʻololi 'eʻike CD19 - antigen ma luna o ka ili o ka maʻi' aʻai keena.

A laila, ua injected hoʻi i loko o ka hoʻomanawanui i kēia mau Hoʻololi 'keena, ma o na la ia e kaua aku i leukemia, a ioioie? No ka hoonui Ka maʻi' aʻai aeee i ka antigen CD19. Ke noiʻi hōʻike ia ma hope o eono, a me ka hapalua mahina i loko o 17 o 24 e hoomanawanui i kaʻeho ua hoʻemi a pau nalowale.

"Mua ia ia i hōʻikeʻia mai ka mea i hiki ke hoʻohana immunotherapy timoralnogo mea loaʻa T keena no ka iapaau ana o nā mea maʻi me ka maʻi lymphocytic leukemia, a hoi no i ka mea kiʻekiʻe-kamepiula pūʻulu - la ke ao i ka kēpau mea kākau Dr. Kailee Turtle, immunotherapy kanaka noiʻi ma ka Fred Hutchinson Center. - Our like hōʻike i ka CAR T aeee mea he nui loa i olelo mua iaʻi lapaʻau no nā mea maʻi me CLL i mea ole hoʻomākaukau lapaʻau "Ibrutinib '."

He aha ka CLL?

Maʻi lymphocytic leukemia - he maʻi e hoomaka ana ma ka iwi ka lolo o ke kanaka (ma ka pahee'aʻaʻa i loko o ka iwi kahi koko aeee i hana). Ma nā mea maʻi me ka CLL, ka iwi lolo produces nui loa'āno'ē lymphocytes ('āno'ēʻano o keʻokeʻo koko aeee).

E like me ka maʻi progresses, i kēia mau'āno'ē keena hiki ke Hoʻohui 'pu, a mahuahua ma ka lymph aka wahi, spleen a me ka akepaʻa. I ka nui o ka "lymphoid hikoko" hiki ke anaia ka hoʻohana acee? Iuo oeiia o kaʻimiʻana.

Healthy keena - o ke kino i ka mea e malu ai aeee e kōkua kaua maʻiʻaʻai, akā, ma nā mea maʻi me ka CLL, aole lakou e Aʻole e holopono ana pololei a me ka i chaos. E like me ka American Cancer Society, maʻi lymphocytic leukemia i ka 2017, e lilo i ke kumu o ka 4660 make. I manaoia e ia ma kahi o 20.110 hou hihia o ka maʻi.

ʻaoʻao waiwai

New Inc he nuiʻaoʻao waiwai, eia nae ka hapanui o ia mau reversible. Ma ke ao ma kahi o 83% o nā mea maʻi ho'āʻo cytokine hoʻokuʻu maʻi pale, o ka hoʻomaopopo like complication ma hope o lapaʻau T-keena me symptoms e like me ke kuni, nausea, ole, a abnormally haahaa ke koko. Eia naʻe, elua o ka hoʻomanawanui iki mai i hospitalized, a me kekahi make i lapaau.

Eha pule ma hope o lapaʻau, ka noiʻi ua kālailai iwi nä lolo Eia kekahi laʻana o ka 12 hoʻomanawanuiʻana, ka mea ma muli o ka lapaʻau he i ke kala, e ike ina paha e waiho wale ana i ka moku'āina ma hope o ka pau ana o Inc. O kēia mau mea, ehiku lakou i malignant Ka maʻi 'aʻai keena.

Ke kuka nei lakou mea nō i loko o kona kahua o ka hoʻonaʻauao i kakahiaka nui, akā, nui ka manaʻolana 'ia, ua mai. ʻaoʻao 'ole i ka manao o ka pilikia, akā, me ka Loaʻaʻia pomaikai me ka nui loa mamua o ko lakou.